14 Aug

What We May See from Amgen’s Vectibix in 2017

WRITTEN BY Daniel Collins

Vectibix’s revenue trends

In 2Q17, Amgen’s (AMGN) Vectibix generated revenues of ~$168 million, which represented a ~5% YoY (year-over-year) rise and a ~14% QoQ (quarter-over-quarter) rise. In the US, Vectibix generated revenues of ~$62 million in 2Q17, or ~19% higher YoY.

Outside the US, Vectibix reported revenues of ~$106 million, or 2% lower YoY and 23% higher QoQ. Shipments of Vectibix to Amgen’s partner in Japan, Takeda Pharmaceuticals, helped boost QoQ revenue growth in 2Q17.

What We May See from Amgen’s Vectibix in 2017

In the US, Vectibix now holds a ~50% market share of the EGFR (epidermal growth factor receptor) inhibitors segment, and Amgen expects further growth in the segment. For more on Vectibix, please refer to Market Realist’s “Nplate and Vectibix Could Contribute to Amgen’s Revenue Growth in 2017.”

Recent regulatory approval

In June 2017, the FDA (US Food and Drug Administration) approved the sBLA (supplemental Biologics License Application) for Vectibix for individuals with wild-type RAS mCRC (metastatic colorectal cancer) as a first-line therapy in combination with Folfox. The FDA also approved Vectibix as a monotherapy when disease progression continues after previous treatment with oxaliplatin, fluoropyrimidine, and irinotecan-containing chemotherapy. This regulatory approval is expected to boost the drug’s revenue growth further.

Notably, Amgen’s Vectibix gives tough competition to Eli Lilly’s (LLY) Erbitux, Roche’s (RHHBY) Avastin, and Bayer’s (BAYZF) Stivarga. Any growth in sales of Amgen’s Vectibix could boost the share prices of the Vanguard Health Care ETF (VHT). Amgen makes up ~3.6% of VHT’s total portfolio holdings.

Latest articles

This year, Pfizer (PFE) stock has fallen 0.34% and Bristol-Myers Squibb (BMY) stock has fallen 6.48%. Both companies are focused on strengthening their position in the high-growth oncology and immunology markets. Let's take a closer look at each.

Walt Disney’s (DIS) latest movie, Toy Story 4, has reportedly broken records in the opening weekend with $118 million in sales. However, the opening weekend collection was behind analysts’ expectations of at least $150 million in the first weekend.

24 Jun

Will Home Depot’s Upward Momentum to Continue?

WRITTEN BY Rajiv Nanjapla

As of June 21, Home Depot (HD) was trading at $209.39, which implies a rise of 9.7% since the announcement of its first-quarter earnings on May 21. Also, the company was trading at a premium of 32.4% from its 52-week low of $158.09 and a discount of 2.8% from its 52-week high of $215.43.

On June 21, Aurora Cannabis (ACB) made an announcement that indicated that it will move towards higher margin vape products. In addition, the company also believes concentrates and edibles will command higher margins. In anticipation of this development, the company announced the expansion of its facility to capitalize on growth related to these segments.

Shares of Mondelēz International (MDLZ) are scaling new heights thanks to its stellar gains so far this year. Mondelēz stock is up 38.0% on a YTD (year-to-date) basis, and it closed at $55.25—just a shade lower than its 52-week high of $55.71—on June 21.

24 Jun

How Long Will Facebook's Libra Fuel Bitcoin Rally?

WRITTEN BY Mayur Sontakke, CFA, FRM

Ever since the news about Facebook’s (FB) cryptocurrency project broke, Bitcoin has rallied on the hope that Facebook’s entry in the space will help make cryptocurrencies mainstream. Facebook’s cryptocurrency will be called Libra and will be governed by an association with 28 founding members across industries.